Logo
x

Search

Subscribe Now

Novaliq

Novaliq’s Vevizye (Ciclosporin) gains the CHMP’s Positive Opinion to Prevent Moderate to Severe Dry Eye Disease (DED)

Novaliq’s Vevizye (Ciclosporin) gains the CHMP’s Positive Opinion to Prevent Moderate to Severe Dry Eye Disease (DED)

  • July 29, 2024
Novaliq Reports the EMA Acceptance of MAA for CyclASol (ciclosporin ophthalmic solution) to Treat Dry Eye Disease

Novaliq Reports the EMA Acceptance of MAA for CyclASol (ciclosporin ophthalmic solution) to Treat Dry Eye Disease

  • August 24, 2023
PharmaShots' Key Highlights of Second Quarter 2022

PharmaShots' Key Highlights of Second Quarter 2022

  • June 30, 2022
Novaliq Presents Results of Cyclasol in P-III (ESSENCE-2) Trial for the Treatment of Dry Eye Disease at ASCRS 2022

Novaliq Presents Results of Cyclasol in P-III (ESSENCE-2) Trial for the Treatment of Dry Eye Disease at ASCRS 2022

  • April 27, 2022
Novaliq Reports Results of CyclASol in P-III (ESSENCE-2) Trial for the Treatment of Dry Eye Disease

Novaliq Reports Results of CyclASol in P-III (ESSENCE-2) Trial for the Treatment of Dry Eye Disease

  • December 22, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.